Intellia Therapeutics (NASDAQ: NTLA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for Intellia Therapeutics and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics 0 3 4 0 2.57
Ironwood Pharmaceuticals 0 6 4 0 2.40

Intellia Therapeutics currently has a consensus price target of $30.17, indicating a potential upside of 60.38%. Ironwood Pharmaceuticals has a consensus price target of $17.88, indicating a potential upside of 16.15%. Given Intellia Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Ironwood Pharmaceuticals.

Volatility and Risk

Intellia Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.

Profitability

This table compares Intellia Therapeutics and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intellia Therapeutics -215.92% -28.01% -19.83%
Ironwood Pharmaceuticals -48.89% -645.22% -19.69%

Institutional & Insider Ownership

49.0% of Intellia Therapeutics shares are owned by institutional investors. 12.8% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Intellia Therapeutics and Ironwood Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intellia Therapeutics $16.48 million 41.19 -$31.63 million ($1.56) -12.06
Ironwood Pharmaceuticals $273.96 million 8.41 -$81.70 million ($0.97) -15.87

Intellia Therapeutics has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Intellia Therapeutics beats Ironwood Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.